Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 2;5(10):e355.
doi: 10.1038/bcj.2015.74.

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients

F Boissard  1   2 , J-J Fournié  1   2 , A Quillet-Mary  1   2 , L Ysebaert  1   2   3 , M Poupot  1   2
Affiliations

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients

F Boissard et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
In vivo ibrutinib treatment does not hamper NLC phenotype and function. (a) NLC were absent from the PB during ibrutinib treatment at the time of blood sampling (left: before ibrutinib treatment, center and right: 15 days and 30 days of ibrutinib treatment, respectively). (Representative results from five independent experiments). (b) Flow cytometry analysis of the expression of CD14, CD163, CD68, CD11b and CD33 by NLC before (day 0, D0) or after ibrutinib treatment of the patient for the times shown (15 days or 1, 3 or 12 months), compared with isotype control (gray) after 15 days of differentiation. (Representative results from five independent experiments). (c) Percentage viability of CLL cells from ibrutinib-treated patients when cultured alone (black line) or with their own NLC (gray line). (Data taken from five independent experiments). (d) Percentage viability of CLL cells from untreated or ibrutinib-treated patients after 12 days of culture either alone or in the presence of NLC from untreated or ibrutinib-treated patients. (Data taken from five independent experiments for ibrutinib-treated patients, seven independent experiments for untreated patients). (*P<0.05 and ***P<0.001).
Figure 2
Figure 2
NLC protect CLL cell survival against ibrutinib at clinical concentrations in vitro. (a) Percentage viability of CLL cells after 7 days of culture either alone or in the presence of NLC treated or not (untreated, UT) with the indicated drugs. (b) Percentage viability of CLL cells after 7 days of culture either alone or in the presence of NLC treated or not (UT) with ibrutinib at the indicated concentrations. (Data taken from eight independent experiments for each indicated drug). (c) Percentage viability of CLL cells after 7 days of culture either alone or in the presence of NLC treated or not (UT) with bendamustin, idelalisib or both. (Data taken from eight independent experiments for each indicated drug). (d) Percentage viability of CLL cells after 7 days of culture either alone or in the presence of NLC treated or not (UT) with bendamustin, ibrutinib or both. (Data taken from eight independent experiments for each indicated drug). (*P<0.05 and **P<0.01).
See this image and copyright information in PMC

References

    1. 1Caligaris-Cappio F, Gottardi D, Alfarano A, Stacchini A, Gregoretti MG, Ghia P et al. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells 1993; 19: 601–613. - PubMed
    1. 2Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592–601. - PMC - PubMed
    1. 3Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007; 2: 58–61. - PubMed
    1. 4Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 1278–1279. - PubMed
    1. 5Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42. - PMC - PubMed

MeSH terms

LinkOut - more resources